Earnings

Intensity Therapeutics Q3 EPS $(1.09) Misses $(0.99) Estimate. Cash and Equivalents $8.5M

Nov 5, 2026 · 07:42 AM ET· updated 2h ago

Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.99) by 10.1 percent. This is a 172.67 percent decrease over earnings of $1.50 per

Why It Matters

Intensity Therapeutics lost more money per share than experts thought it would. Watch how fast they're spending their remaining $8.5 million cash.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

INTS3.50

+0.12 (+3.55%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.